Generated by AI
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing targeted protein degradation medicines. Nurix Therapeutics develops small-molecule and antibody-based therapies designed to modulate cellular protein levels through the ubiquitin-proteasome system, with applications in oncology, immunology, and inflammatory diseases. Its current pipeline includes investigational programs aimed at B-cell malignancies, immune-mediated disorders, and other serious conditions, supported by its DELigase discovery platform and expertise in E3 ligases. The company also advances partnered research and development programs with major pharmaceutical collaborators, combining internal drug discovery capabilities with broader development and commercialization efforts. Headquartered in San Francisco, California, Nurix Therapeutics plays a specialized role in the biotechnology market by translating protein degradation science into potential therapeutic candidates for diseases with limited treatment options.
Website1600 Sierra Point Parkway
Brisbane, CA, 94005
United States
The latest articles about NRIX.
Summary of Oct 12's posts. Generated by AI.
Summary of Jun 9's posts. Generated by AI.
Summary of Jun 8's posts. Generated by AI.
Summary of Jun 27's posts. Generated by AI.
Investors talking about NRIX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.